H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Nemaura Medical to $2.50 from $7 and keeps a Buy rating on the shares. The firm expects the company to ramp up revenue via global partnerships in the coming years. but says its original projections for the sales trajectory may be too optimistic.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NMRD: